What is Cellphire?
Cellphire Therapeutics is a life sciences company focused on developing advanced platelet-based therapies to combat controllable hemorrhage, a critical factor in preventable deaths. Their product pipeline includes freeze-dried platelet-derived hemostats (FPH) and Cryopreserved Platelets (CPP), both of which are undergoing Phase 2 clinical trials. These therapies are designed to enhance hemostatic efficacy for both military personnel and civilian patients, particularly in emergency and surgical settings. The company's overarching mission is to ensure that effective bleeding control treatments are accessible, driven by a vision to eliminate fatalities from controllable hemorrhage.
How much funding has Cellphire raised?
Cellphire has raised a total of $20.6M across 5 funding rounds:
Debt
$1M
Other Financing Round
$1.3M
Other Financing Round
$3M
Debt
$350K
Series A
$15M
Debt (2014): $1M, investors not publicly disclosed
Other Financing Round (2016): $1.3M led by Maryland Department of Commerce
Other Financing Round (2017): $3M supported by Maryland Department of Commerce
Debt (2020): $350K featuring PPP
Series A (2021): $15M backed by Simcah Management
Key Investors in Cellphire
Simcah Management
Simcah Management is an investor participating in Cellphire's Series A funding round, indicating a strategic interest in the company's therapeutic development.
Maryland Department of Commerce
The Maryland Department of Commerce has provided financing to Cellphire, supporting the company's growth and development initiatives within the state.
PPP
Public-Private Partnership
What's next for Cellphire?
The recent major strategic investment signifies a pivotal moment for Cellphire, likely enabling the acceleration of its clinical development programs and the progression of its platelet therapeutics towards market approval. This infusion of capital is expected to support further research, expand manufacturing capabilities, and facilitate broader clinical trial participation. Cellphire's focus on addressing a critical unmet medical need in hemorrhage control positions it for significant growth and impact within the emergency medicine and trauma care sectors.
See full Cellphire company page
